KURA – Kura Oncology, Inc.
Kura Oncology, Inc.KURA
$5.92Name : Kura Oncology, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $512,522,240.00
EPSttm : -2.09
Kura Oncology, Inc.
$5.92
2.07%$0.12Float Short %
10.25
Margin Of Safety %
-20
Put/Call OI Ratio
0.11
EPS Next Q Diff
0.04
EPS Last/This Y
-0.16
EPS This/Next Y
0.08
Price
5.8
Target Price
26.25
Analyst Recom
1.33
Performance Q
-30.46
Relative Volume
0.79
Beta
0.43
Ticker: KURA
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-04-14 | KURA | 5.84 | 0.19 | 0.00 | 5427 |
| 2025-04-15 | KURA | 6.02 | 0.19 | 0.00 | 5443 |
| 2025-04-16 | KURA | 5.74 | 0.18 | 5.00 | 5563 |
| 2025-04-17 | KURA | 5.89 | 0.18 | 5.00 | 5563 |
| 2025-04-18 | KURA | 5.9 | 0.18 | 5.00 | 5563 |
| 2025-04-21 | KURA | 6.18 | 0.15 | 0.00 | 3759 |
| 2025-04-22 | KURA | 6.3 | 0.15 | 0.30 | 3759 |
| 2025-04-23 | KURA | 6.35 | 0.15 | 0.00 | 3845 |
| 2025-04-24 | KURA | 6.41 | 0.15 | 0.00 | 3845 |
| 2025-04-25 | KURA | 6.43 | 0.14796366832699 | 0 | 3918 |
| 2025-04-28 | KURA | 6.51 | 0.14671702498547 | 0 | 3947 |
| 2025-04-29 | KURA | 6.51 | 0.15 | 0.00 | 3947 |
| 2025-04-30 | KURA | 6.55 | 0.15 | 0.00 | 3947 |
| 2025-05-01 | KURA | 6.46 | 0.15 | 0.18 | 3967 |
| 2025-05-02 | KURA | 6.47 | 0.15 | 0.00 | 4567 |
| 2025-05-05 | KURA | 6.71 | 0.14 | 0.00 | 4781 |
| 2025-05-06 | KURA | 5.78 | 0.11 | 0.37 | 5947 |
| 2025-05-07 | KURA | 5.64 | 0.11 | 0.00 | 6108 |
| 2025-05-08 | KURA | 5.99 | 0.11 | 0.00 | 6316 |
| 2025-05-09 | KURA | 5.76 | 0.11 | 0.00 | 6436 |
| 2025-05-12 | KURA | 6.08 | 0.11 | 0.00 | 6504 |
| 2025-05-13 | KURA | 5.76 | 0.11 | 0.00 | 6624 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-04-14 | KURA | 5.85 | -6.6 | - | -2.19 |
| 2025-04-15 | KURA | 6.03 | -1.7 | - | -2.19 |
| 2025-04-16 | KURA | 5.74 | -1.7 | - | -2.19 |
| 2025-04-17 | KURA | 5.90 | -1.7 | - | -2.19 |
| 2025-04-18 | KURA | 5.90 | -1.7 | - | -2.19 |
| 2025-04-21 | KURA | 6.18 | -1.7 | - | -2.19 |
| 2025-04-22 | KURA | 6.31 | -1.7 | - | -2.19 |
| 2025-04-23 | KURA | 6.37 | -1.7 | - | -2.19 |
| 2025-04-24 | KURA | 6.42 | -1.7 | - | -2.19 |
| 2025-04-25 | KURA | 6.43 | -1.7 | - | -2.19 |
| 2025-04-28 | KURA | 6.51 | -1.7 | - | -2.19 |
| 2025-04-29 | KURA | 6.52 | -1.7 | - | -2.19 |
| 2025-04-30 | KURA | 6.56 | -1.7 | - | -2.19 |
| 2025-05-01 | KURA | 6.49 | -1.7 | - | -2.19 |
| 2025-05-02 | KURA | 6.47 | -1.7 | - | -2.19 |
| 2025-05-05 | KURA | 6.72 | 9.7 | - | -2.54 |
| 2025-05-06 | KURA | 5.78 | 22.5 | - | -2.54 |
| 2025-05-07 | KURA | 5.64 | 22.5 | - | -2.54 |
| 2025-05-08 | KURA | 5.99 | 27.8 | - | -2.54 |
| 2025-05-09 | KURA | 5.76 | 27.8 | - | -2.18 |
| 2025-05-12 | KURA | 6.09 | 27.8 | - | -2.18 |
| 2025-05-13 | KURA | 5.80 | 27.8 | - | -2.18 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-04-14 | KURA | -0.81 | 0.63 | 11.71 |
| 2025-04-15 | KURA | -0.81 | 0.63 | 11.71 |
| 2025-04-16 | KURA | -0.81 | 0.63 | 11.71 |
| 2025-04-17 | KURA | -0.81 | 0.63 | 11.71 |
| 2025-04-18 | KURA | -0.81 | 0.63 | 11.71 |
| 2025-04-21 | KURA | -0.81 | 0.77 | 11.71 |
| 2025-04-22 | KURA | -0.81 | 0.77 | 11.71 |
| 2025-04-23 | KURA | -0.81 | 0.77 | 11.68 |
| 2025-04-24 | KURA | -0.84 | 0.77 | 11.68 |
| 2025-04-25 | KURA | -0.84 | 0.77 | 11.68 |
| 2025-04-28 | KURA | -0.84 | -3.05 | 11.51 |
| 2025-04-29 | KURA | -0.84 | -3.05 | 11.51 |
| 2025-04-30 | KURA | -0.84 | -3.05 | 11.51 |
| 2025-05-01 | KURA | -0.84 | -3.05 | 11.51 |
| 2025-05-02 | KURA | -0.84 | -3.05 | 11.51 |
| 2025-05-05 | KURA | -0.84 | -3.54 | 11.51 |
| 2025-05-06 | KURA | -0.84 | -3.54 | 11.51 |
| 2025-05-07 | KURA | -0.79 | -3.54 | 10.74 |
| 2025-05-08 | KURA | -0.79 | -3.54 | 10.74 |
| 2025-05-09 | KURA | -0.79 | -3.54 | 10.74 |
| 2025-05-12 | KURA | -0.79 | 7.71 | 10.25 |
| 2025-05-13 | KURA | -0.79 | 7.71 | 10.25 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.66
Avg. EPS Est. Current Quarter
-0.43
Avg. EPS Est. Next Quarter
-0.62
Insider Transactions
-0.79
Institutional Transactions
7.71
Beta
0.43
Average Sales Estimate Current Quarter
66
Average Sales Estimate Next Quarter
20
Fair Value
4.66
Quality Score
29
Growth Score
27
Sentiment Score
3
Actual DrawDown %
86.5
Max Drawdown 5-Year %
-86.5
Target Price
26.25
P/E
Forward P/E
PEG
P/S
7.39
P/B
1.29
P/Free Cash Flow
4.54
EPS
-2.09
Average EPS Est. Cur. Y
-2.18
EPS Next Y. (Est.)
-2.1
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-267.52
Relative Volume
0.79
Return on Equity vs Sector %
-73.6
Return on Equity vs Industry %
-56.7
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.06
EBIT Estimation
Kura Oncology, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 192
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC. The company is headquartered in San Diego, California.
stock quote shares KURA – Kura Oncology, Inc. Stock Price stock today
news today KURA – Kura Oncology, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch KURA – Kura Oncology, Inc. yahoo finance google finance
stock history KURA – Kura Oncology, Inc. invest stock market
stock prices KURA premarket after hours
ticker KURA fair value insiders trading